These findings may either be explained by intra-tumor heterogeneity as suggested by Platt et al., or that the biological consequences of activating FGFR3 and RAS mutations do not overlap completely and therefore double mutants may result in an additive but small selective advantage. The gene discussed is FGFR3; the disease is neoplasm.